JP2005526713A - 慢性的疼痛、興奮毒性に関連した脳障害及び心臓不整脈の治療へのアンブロキソールの使用 - Google Patents

慢性的疼痛、興奮毒性に関連した脳障害及び心臓不整脈の治療へのアンブロキソールの使用 Download PDF

Info

Publication number
JP2005526713A
JP2005526713A JP2003561587A JP2003561587A JP2005526713A JP 2005526713 A JP2005526713 A JP 2005526713A JP 2003561587 A JP2003561587 A JP 2003561587A JP 2003561587 A JP2003561587 A JP 2003561587A JP 2005526713 A JP2005526713 A JP 2005526713A
Authority
JP
Japan
Prior art keywords
ambroxol
treatment
pharmaceutical composition
pain
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003561587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526713A5 (https=
Inventor
ヴォルフラム ガイダ
クラウス クリンダー
トーマス ヴァイザー
Original Assignee
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト filed Critical ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Publication of JP2005526713A publication Critical patent/JP2005526713A/ja
Publication of JP2005526713A5 publication Critical patent/JP2005526713A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003561587A 2002-01-25 2003-01-21 慢性的疼痛、興奮毒性に関連した脳障害及び心臓不整脈の治療へのアンブロキソールの使用 Pending JP2005526713A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10203104A DE10203104A1 (de) 2002-01-25 2002-01-25 Ambroxol für die Behandlung chronischer Schmerzen
PCT/EP2003/000531 WO2003061642A1 (de) 2002-01-25 2003-01-21 Verwendung von ambroxol zur behandlung von chronischen schmerzen, cerebralen exzitotoxizitätsbedingten störungen und kardialen arrhythmien

Publications (2)

Publication Number Publication Date
JP2005526713A true JP2005526713A (ja) 2005-09-08
JP2005526713A5 JP2005526713A5 (https=) 2006-03-09

Family

ID=7713171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003561587A Pending JP2005526713A (ja) 2002-01-25 2003-01-21 慢性的疼痛、興奮毒性に関連した脳障害及び心臓不整脈の治療へのアンブロキソールの使用

Country Status (11)

Country Link
EP (1) EP1471899B1 (https=)
JP (1) JP2005526713A (https=)
AR (1) AR038316A1 (https=)
AT (1) ATE376416T1 (https=)
CA (1) CA2473885C (https=)
DE (2) DE10203104A1 (https=)
ES (1) ES2295588T3 (https=)
PE (1) PE20040176A1 (https=)
TW (1) TW200307534A (https=)
UY (1) UY27620A1 (https=)
WO (1) WO2003061642A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513551A (ja) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 急性疼痛の治療のためのアンブロキソール
JP2009513549A (ja) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癲癇の治療のためのアンブロキソール

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10332487A1 (de) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen
US20050027012A1 (en) * 2003-07-16 2005-02-03 Boehringer Ingelheim International Gmbh Tablets containing ambroxol
DE102004021992A1 (de) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topische Zubereitung enthaltend Ambroxol
DE102007000521A1 (de) 2007-10-18 2009-04-23 Renate Conrad Hustenpräparat
JP6871400B2 (ja) 2016-11-14 2021-05-12 ミングゥ・ワン 眼表面疾患の治療のための製剤および関連方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000080034A (ja) * 1998-09-02 2000-03-21 Taisho Pharmaceut Co Ltd 風邪用組成物
JP2001151677A (ja) * 1999-11-26 2001-06-05 Taisho Pharmaceut Co Ltd 咽頭用組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08506808A (ja) * 1992-12-21 1996-07-23 ザ、プロクター、エンド、ギャンブル、カンパニー 呼吸障害治療用組成物の製造における鎮痛剤ｓ（＋）対掌体の利用
CN1220598A (zh) * 1996-05-02 1999-06-23 大正制药株式会社 水难溶性酸性药物的悬浮液

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000080034A (ja) * 1998-09-02 2000-03-21 Taisho Pharmaceut Co Ltd 風邪用組成物
JP2001151677A (ja) * 1999-11-26 2001-06-05 Taisho Pharmaceut Co Ltd 咽頭用組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513551A (ja) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 急性疼痛の治療のためのアンブロキソール
JP2009513549A (ja) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癲癇の治療のためのアンブロキソール

Also Published As

Publication number Publication date
DE10203104A1 (de) 2003-08-07
ATE376416T1 (de) 2007-11-15
TW200307534A (en) 2003-12-16
CA2473885A1 (en) 2003-07-31
AR038316A1 (es) 2005-01-12
ES2295588T3 (es) 2008-04-16
EP1471899B1 (de) 2007-10-24
UY27620A1 (es) 2003-08-29
PE20040176A1 (es) 2004-04-16
WO2003061642A1 (de) 2003-07-31
DE50308460D1 (de) 2007-12-06
CA2473885C (en) 2011-03-22
EP1471899A1 (de) 2004-11-03

Similar Documents

Publication Publication Date Title
DE69921157T2 (de) Verwendungsmethoden und zusammenstellungen die einen dopaminewiederaufnahmeinhibitor enthalten
US8420624B2 (en) Methods for treating or preventing symptoms of hormonal variations
JP2008540356A (ja) 薬物乱用の治療方法
JP6216768B2 (ja) 運動障害の管理の改善に適した経口投与可能な医薬製剤
CA2383785C (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
EA007274B1 (ru) Применение флибансерина для лечения половых расстройств
JP2021080276A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2009536176A (ja) 閉経後の性的欲求障害の治療のためのフリバンセリンの使用
RS60152B1 (sr) Tapentadol za sprečavanje i lečenje depresije i anksioznosti
JP2007533687A (ja) 月経前の及び他の女性の性的障害の治療におけるフリバンセリンの使用
WO1997029739A2 (en) Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
CN1141937C (zh) 含有曲马朵的药物组合物用于制备治疗偏头痛或类偏头痛的药物
CZ300549B6 (cs) Farmaceutický prostredek s obsahem cilobradinu
JP2009513604A (ja) 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US20060199867A1 (en) Ambroxol for the treatment of chronic pain
JP2005526713A (ja) 慢性的疼痛、興奮毒性に関連した脳障害及び心臓不整脈の治療へのアンブロキソールの使用
US20050014845A1 (en) Ambroxol for the treatment of epilepsy
SK14552001A3 (sk) Použitie osanetantu na prípravu farmaceutických prostriedkov použiteľných na liečenie porúch nálady
BR112019018700A2 (pt) composições farmacêuticas e seus usos
US20080058345A1 (en) Combination Therapy with Mecamylamine for the Treatment of Mood Disorders
JP2002524508A (ja) 新規組成物
JP2010518040A (ja) 不眠症を治療するためのフリバンセリンの使用
HK1127471A (en) Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
DE19920491A1 (de) Medikament zur Therapie der männlichen Infertilität
HK1091418B (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091020

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100607